Trial · NCT02233023
Ophthalmologic Safety of Long Term Treatment With Pramipexole Compared to Bromocriptine or Other Dopamine Agonists in Patients With Parkinson's Disease
NCT02233023, Phase 4, Completed, Boehringer Ingelheim
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Ophthalmologic Safety of Long Term Treatment With Pramipexole Compared to Bromocriptine or Other Dopamine Agonists in Patients With Parkinson's Disease. Trials, record NCT02233023. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT02233023
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Ophthalmologic Safety of Long Term Treatment With Pramipexole Compared to Bromocriptine or Other Dopamine Agonists in Patients With Parkinson's Disease
- NCT number
- NCT02233023
- Status
- Completed
- Phases
- Phase 4
- Enrollment
- 705 participants, actual
- Lead sponsor
- Boehringer Ingelheim
- Conditions
- Parkinson Disease
- Interventions
- Pramipexole, Bromocriptine and other dopamine agonists
- First posted
- 2014-09-08
- Last updated
- 2014-09-08
Source ClinicalTrials.gov
Registered outcomes12
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Incidence of drug related signs of retinal degeneration | up to 8 months | based on the evaluation of assessors blind to the treatment allocation |
| Secondary | Assessment of ophthalmological history | within 2 month after neurologic visit | |
| Secondary | Assessment of visual acuity | within 2 month after neurologic visit | |
| Secondary | Number of abnormal findings in clinical examination in miosis and mydriasis | within 2 month after neurologic visit | including ophthalmoscopy |
| Secondary | Assessment of intraocular pressure (mmHg) | within 2 month after neurologic visit | |
| Secondary | Assessment of colour vision | within 2 month after neurologic visit | using the Hardy-Rand-Rittler (H-R-R) pseudoisochromatic plates |
| Secondary | Findings in kinetic perimetry | within 2 month after neurologic visit | |
| Secondary | Percentage of patients with elevated dark adaptation thresholds | within 2 month after neurologic visit | |
| Secondary | Assessment of Parkinson's Disease stage rated by modified Hoehn and Yahr Scale | within less than 2 months before ophthalmologic visit | |
| Secondary | Assessment of Parkinson's Disease stage rated of unified Parkinson's Disease Rating Scale (UPDRS) Part IV | within less than 2 months before ophthalmologic visit |
1 to 10 of 12Source ClinicalTrials.gov
See all 12 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT02233023
GET https://conductscience.org/api/trials/v1/NCT02233023/registered